# ASTRAZEN — AstraZeneca Pharma India Limited

> AstraZeneca Pharma India Limited (ASTRAZEN) on the NSE: 4,787 sessions of split-adjusted history from 2007.

Canonical: https://patternsradar.com/s/ASTRAZEN

## Latest session

- Close: 7,415.5 INR (-1.22% on the day), 2026-08-21
- Delivery: 58.22% of volume taken to demat (20-day average 53.54%)
- Volume: 19.2K shares, turnover ₹14.2Cr
- Relative volume: 1.06× of its own 20-day average

## Technicals

- RSI(14): 27.48
- ATR(14): 196.86
- SMA 50: 8,119.46, SMA 200: 8,533.51
- 52-week range: 7,371.5 – 9,849.5 (-24.71% from the high)

## Performance

- 1 week -4.35%, 1 month -5.8%, 3 months -13.65%
- 6 months -16.72%, 1 year -11.89%

## Fundamentals

- Market cap: 18,538.8 crore
- P/E (TTM): 109.3 — NULL when trailing earnings are negative or unfiled, never a misleading number
- EPS (TTM): 67.85 INR, split-adjusted to match the price series
- Revenue growth: 29.73% YoY, 18.01% QoQ
- Profit growth: -32.06% YoY, -15.49% QoQ

Compound annual growth, trailing-twelve-month against the same measure N years earlier:

| Window | Revenue | Profit |
| --- | --- | --- |
| 2y | 32.39% | 33.02% |
| 3y | 31.64% | 8.44% |
| 4y | 29.58% | 24.11% |
| 5y | 25.05% | 14.84% |
| 6y | -0.87% | -5.43% |
| 7y | 17.83% | 13.58% |

## Quarterly results

Last 8 filed quarters, standalone basis, in rupees crore as filed.

| Quarter | Revenue | Total expenses | Profit before tax | Net profit | EPS | Net margin |
| --- | --- | --- | --- | --- | --- | --- |
| 2024-09-30 | 408 | 365.1 | 51 | 38.4 | 15.37 | 9.42% |
| 2024-12-31 | 440.3 | 372.7 | 42 | 30.9 | 12.34 | 7.01% |
| 2025-03-31 | 480.5 | 412.5 | 78.5 | 58.3 | 23.3 | 12.12% |
| 2025-06-30 | 526.3 | 462.5 | 74.7 | 55.8 | 22.33 | 10.61% |
| 2025-09-30 | 559.1 | 487.2 | 72.8 | 54.2 | 21.69 | 9.7% |
| 2025-12-31 | 611.6 | 571.6 | 46.5 | 32.6 | 13.04 | 5.33% |
| 2026-03-31 | 578.6 | 525.3 | 58.1 | 44.9 | 17.95 | 7.76% |
| 2026-06-30 | 682.8 | 641 | 50.8 | 37.9 | 15.17 | 5.56% |

A quarterly filing with NSE carries a profit and loss only. There is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure in this dataset. EPS is restated onto the split-adjusted basis the price series uses; every rupee figure is exactly as filed.

## Shareholding

As filed for 2026-06-30:

- Promoter: 75%
- Public: 25%

Institutional and pledge percentages come from a filing stage whose backfill has reached about 1% of instruments, so they are absent here rather than zero.

## Recent filings

- 2026-08-11: results for 2026-06-30 standalone — https://nsearchives.nseindia.com/corporate/ixbrl/INTEGRATED_FILING_INDAS_184932_11082026125612_iXBRL_WEB.html
- 2026-07-31: dividend
- 2026-07-20: shareholding for 2026-06-30 — https://nsearchives.nseindia.com/corporate/xbrl/SHP_1697186_20072026055135_WEB.xml
- 2026-05-26: results for 2026-03-31 standalone — https://nsearchives.nseindia.com/corporate/ixbrl/INTEGRATED_FILING_INDAS_161531_26052026195308_iXBRL_WEB.html
- 2026-04-20: shareholding for 2026-03-31 — https://nsearchives.nseindia.com/corporate/xbrl/SHP_1655030_20042026042416_WEB.xml
- 2026-02-11: results for 2025-12-31 standalone — https://nsearchives.nseindia.com/corporate/ixbrl/INTEGRATED_FILING_INDAS_142110_11022026192416_iXBRL_WEB.html
- 2026-01-20: shareholding for 2025-12-31 — https://nsearchives.nseindia.com/corporate/xbrl/SHP_1605755_20012026045616_WEB.xml
- 2025-11-07: results for 2025-09-30 standalone — https://nsearchives.nseindia.com/corporate/ixbrl/INTEGRATED_FILING_INDAS_125197_07112025183020_iXBRL_WEB.html

Dated by the day the company broadcast the filing. 112 events are indexed for this instrument.

## About the instrument

- Listed: 2007-04-10 — latest session 2026-08-21 (4,787 sessions)
- ISIN: INE203A01020
- Series: EQ
- Liquidity rank: #896 by 20-day average turnover — not index membership

Delivery figures come from NSE's daily reports and are unavailable for older sessions. Prices are end-of-day, split- and bonus-adjusted, from the eod2 dataset.

Charts and the full bar history are on the rendered page: https://patternsradar.com/s/ASTRAZEN.